Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02902081 · ClinicalTrials.gov registry record · NA

Cannabidiol and Emotional Stimuli

A NA study of Drug Addiction, sponsored by University of Chicago.

Completed
Registry status
NA
Development phase
38
Enrollment target
1
Study location

NCT02902081: Completed NA study of Drug Addiction, sponsored by University of Chicago.

NCT02902081 is a NA study of Drug Addiction that has completed, run by University of Chicago. The registered enrollment target is 38 participants, below the 105-participant average among 13 other Drug Addiction trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02902081, a NA study of Drug Addiction, has completed, sponsored by University of Chicago.

COMPLETED
Registry status
NA
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to examine the effect of cannabidiol (CBD), a cannabinoid compound found in marijuana, on responses to emotional stimuli. Both preclinical and clinical studies indicate that CBD may act to reduce anxiety without excessive sedative side-effects. Thus the investigators hypothesize that CBD may reduce responses specifically to negative emotional and social stimuli, including pictures and emotional faces, without altering responses to positive stimuli. To examine this, the investigators will administer placebo, 300mg, 600mg, and 900mg CBD to healthy normal adults in a double-blind within-subjects study. The investigators will measure subjective and subtle physical responses to positive and negative stimuli using measures that have been characterized with classic anxiety-reducing drugs and drugs of abuse. Further, the investigators will examine whether CBD-induced changes in these measures of emotional response relate to changes in actual behavior in a controlled social interaction. These results will allow the investigators to examine the potential usefulness of CBD as an anxiety-reducing drug, and suggest mechanisms by which CBD may reduce anxiety.

Primary Outcome

Using the International Affective Picture System (IAPS; Lang et al. 1999), participants viewed standardized positive, negative and neutral pictures from the IAPS. The negative and positive images were matched on degree of valence and arousal. An Evaluative Space Grid rating followed each picture to collect subjective reactions. Ratings are on a 9-pt scale. The range of the scale is from 1 to 9 (Min score 1, max score 9). The total score is reported. Higher numbers represent more positive valence

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Cannabidiol

Study Locations (1)

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2013-02
Est. Completion 2017-03
Phase NA
University of Chicago

796 total trials

What the finished NCT02902081 record still lists

NCT02902081 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 105-participant average among 13 other Drug Addiction trials with a reported enrollment target (64% lower).

The record links to 1 condition, with Drug Addiction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02902081 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT02902081 about?

NCT02902081 is a clinical study titled "Cannabidiol and Emotional Stimuli". The purpose of this research is to examine the effect of cannabidiol (CBD), a cannabinoid compound found in marijuana, on responses to emotional stimuli. Both preclinical and clinical studies indicate that CBD may act to reduce anxiety without excessive sedative side-effects. Thus the investigators ...

What is the current status of trial NCT02902081?

This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2013-02. Estimated completion is 2017-03.

What conditions does trial NCT02902081 study?

This clinical trial studies the following conditions: Drug Addiction.

What interventions are being tested in trial NCT02902081?

The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).

Who is sponsoring clinical trial NCT02902081?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02902081 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Drug Addiction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02902081's enrollment target sits among peer trials

38 13th of 13 higher than 1 of 13 other Drug Addiction trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Drug Addiction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02902081, the US trial registry maintained by the National Library of Medicine. NCT02902081 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.